The Prevacus Story

prevacus-story

Spun out of Florida State University, Prevacus is a development stage company focusing on a new treatment for concussions, a.k.a., mild traumatic brain injuries or mTBI. TBI touches many lives and is a major cause of disability worldwide. Particularly vulnerable are athletes, the military, the elderly and victims of motor vehicle accidents.

Currently, there are no drugs available for concussion treatment – just rehabilitation and rest. Prevacus’ founder, Jacob VanLandingham is a Ph.D. working in the Department of Biomedical Sciences for the FSU College of Medicine. He has spent many years in the laboratory analyzing the positive effects neuro-steroids have on edema – swelling of the brain. However, the sexual and clotting side effects of some neuro-steroids limit their use. The Prevacus scientific team is in the process of developing an alternate line of concussion therapies and is currently evaluating the safety and efficacy of these drugs in preparation for bringing these products to market. Further, Prevacus is in the early stages of novel drug testing in animals for other neurodegenerative disorders, including Alzheimer’s disease.

Recent News
  • Brett Favre, Concussion Victim, Is Backing Research into a Concussion Drug

    By JENNY VRENTAS November 07, 2017 On the last play of Brett Favre’s football career, he suffered a concussion. In the seven years since his retirement, the Hall of Fame quarterback has become increasingly honest regarding his concerns about the long-term consequences of the sport through which he made his name. There are times Favre will run into […]

    Read More »

  • A Local Solution for Concussion ‘Epidemic’: Prevacus Could be a Football Sideline Staple

    The Prevacus story starts in Tallahassee, specifically at Florida High and Florida State University. Where the story ends is uncertain because nobody has all the answers concerning the long-term effects of concussions. However, the potentially groundbreaking drug could help change that. Prevacus is being developed by Jake VanLandingham, a neuroscientist and a former member of […]

    Read More »

  • Can this Drug Save Football?

    Brett Favre had a 20-year career in the NFL, including an iron-man stint in which he played in 321 straight games. But it was his last play in the league that was a painful exclamation point on his illustrious tenure. In December 2010, while playing for the Vikings, the quarterback was sacked and knocked out […]

    Read More »

  • Prevacus Announces the Addition of Key Individuals to its Sports Advisory Board

    TALLAHASSEE, Fla., Feb. 22, 2017 (GLOBE NEWSWIRE) — Prevacus, Inc., a leading biopharmaceutical company focused on developing treatments for concussion (mild traumatic brain injury (mTBI)) and other neurological disorders; today announced the addition of Steve Mariucci, Eddie DeBartolo Jr., Matt Hasselbeck and Warren Moon to its sports advisory board. “I am delighted to have the […]

    Read More »

  • Prevacus Announces Appearance on Fox Business

    TALLAHASSEE, Fla., Feb. 15, 2017 (GLOBE NEWSWIRE) — Prevacus, Inc., a leading biopharmaceutical company focused on developing treatments for concussion (mild traumatic brain injury (mTBI)) and other neurological disorders; today announced that Dr. Jake VanLandingham and investor Brett Favre appeared on Fox Business’ “Mornings with Maria” on Friday, February 10, 2017 to discuss the Company’s […]

    Read More »